About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer’s disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson’s disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142
Biogen Inc News and around…
Latest news about Biogen Inc (BIIB) common stock and company :
Over the past 3 months, 13 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed ...
Biogen(NASDAQ:BIIB) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know ...
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022. The planned initial submission package will seek approval of zuranolone for the treatment of major depressive disorder (MDD) and an additional filing for postpartum depression (PPD) is anticipated in the first half of 2023. The decision to submit the application follows recent discussions with the FDA, including a pre-NDA meeting held this fall. Data from completed studies in the LANDSCAPE and NEST programs, as well as data from the ongoing clinical and pharmacology studies, are planned to be included as part of the submission packages.
CAMBRIDGE, Mass., October 19, 2021--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022. The planned initial submission package will seek approval of zuranolone for the treatment of major depressive disorder (MDD) and an additional filing for postpartum depression (PPD) is
Shares of the biotech companies are slumping after the failure of a trial for its treatment for amyotrophic lateral sclerosis.
Biogen and Ionis' approach to Lou Gehrig's disease flopped over the weekend, leading IONS stock to collapse to a five-year low Monday.
Stocks wavered on Monday as concern about surging inflation pressure and a weakened China growth rate tamed optimism into third-quarter earnings season. Here are some of the laggards in the stock market on Friday. Shares of Zillow tumbled Monday after the online real estate services company reportedly paused its home-buying service as it worked through a backlog of properties.
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.
Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.
Biogen is engaging with regulators, the medical community, patient groups and other key stakeholders around the world to determine its potential next steps.
Biogen Inc(NASDAQ: BIIB)has announced topline resultsfrom its Phase 3 VALOR study of tofersen (BIIB067), an ...
Shares of Biogen were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS) drug did not meet the primary endpoint in an open-label, Phase 3 clinical trial. Biogen said it is considering next steps for the investigational drug, tofersen, which was being tested in people with a rare form of the neurodegenerative disease. "These preliminary data may be supportive of some hints of efficacy; however, the study failed the well-und
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market ...
Our call of the day from Jim Bianco sees one big reason for bitcoin's recent climb, as investors wait for news of an ETF. And here's a bullish bitcoin chart.
By Dhirendra Tripathi
Stocks slip lower into busy earnings week; China GDP slows amid power crisis; Apple event to focus on newly-designed MacBook; Biogen gets mixed results in ALS trial and Delta-plus virus triggers COVID case surge in Britain.
A late-stage trial of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach its main goal, but secondary measures and biomarkers showed favorable trends, the company said on Sunday. Biogen will engage with regulators and other stakeholders "to understand the meaningfulness of this data and potential paths forward," Toby Ferguson, head of the neuromuscular development unit at Biogen, told Reuters. The company is treating trial patients in a follow-on study and recently launched a Phase 3 trial of the drug, tofersen, in patients who are not yet experiencing ALS symptoms.
In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observedThe totality of evidence from VALOR and its ongoing open-label extension showed that participants who started tofersen earlier experienced better outcomes, further suggesting a positive clinical effectTopline
A traditionally troublesome month is turning out to be anything but for the stock market…so far.
These two novel-drug makers could be top takeover targets next year.
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it becomes profitable, investors will come flocking back.
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...
In early trading on Friday, shares of Marriott International, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.2%. Year to date, Marriott International, registers a 20.3% gain.
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
There are good reasons behind analysts' optimism about these stocks.
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021. ANA Presentation Details:Sunday, October 17, 2021, 4:20 p
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower risk of relapse for patients treated with TYSABRI® compared to Ocrevus® (ocrelizumab)New data from EVOLVE-MS-2 demonstrate that a favorable gastrointestinal (GI) tolerability profile for VUMERITY® (diroximel fumarate) is achieved and maintained with dose titration CAMBRIDGE, Mass., Oct. 13, 202
MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest that approximately 40 percent of people with MS treated with anti-CD20 and S1P disease-modifying therapies (DMT) mount an antibody response to the COVID-19 vaccineCollaborative MS PATHS network enabled rapid collection of data in the COVID-19 environment CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE